AIMS: βIII-tubulin (TUBB3) is a microtubule component overexpression of which is found in many solid cancer types, often linked to poor patient prognosis, and has been suggested to predict failure of microtubule-targeting chemotherapeutics. This study was designed to determine prevalence and prognostic impact of TUBB3 expression in kidney cancers. METHODS AND RESULTS: A tissue microarray (TMA) containing more than 1,200 renal tumors was analyzed by immunohistochemistry. TUBB3 expression varied markedly between the different histological subtypes and was more frequent in 105 papillary cancers (75.2 %, p < 0.0001), 38 oncocytomas (52.6 %, p < 0.0001), and 22 chromophobic carcinomas (36.4 %, p = 0.1221) than in 555 clear cell RCC (16.4 %). In clear cell cancers, strong TUBB3 positivity was linked to high Fuhrman grade (p < 0.0001), advanced stage (0.002), nodal metastases (p = 0.0433), hematogenous metastases (p = 0.0016), and shortened overall survival (p < 0.0001). Associations with outcome and tumor phenotype were inversely for papillary RCC, where TUBB3 immunostaining was linked to low tumor stage (p = 0.0012) and prolonged survival (p = 0.0043). CONCLUSIONS: TUBB3 expression levels and their effects are strikingly different between ccRCC and papillary RCC. These differences may be caused by differences in VHL function between these RCC subtypes, because VHL (like TUBB3) is another strong regulator of microtubule function.
AIMS: βIII-tubulin (TUBB3) is a microtubule component overexpression of which is found in many solid cancer types, often linked to poor patient prognosis, and has been suggested to predict failure of microtubule-targeting chemotherapeutics. This study was designed to determine prevalence and prognostic impact of TUBB3 expression in kidney cancers. METHODS AND RESULTS: A tissue microarray (TMA) containing more than 1,200 renal tumors was analyzed by immunohistochemistry. TUBB3 expression varied markedly between the different histological subtypes and was more frequent in 105 papillary cancers (75.2 %, p < 0.0001), 38 oncocytomas (52.6 %, p < 0.0001), and 22 chromophobic carcinomas (36.4 %, p = 0.1221) than in 555 clear cell RCC (16.4 %). In clear cell cancers, strong TUBB3 positivity was linked to high Fuhrman grade (p < 0.0001), advanced stage (0.002), nodal metastases (p = 0.0433), hematogenous metastases (p = 0.0016), and shortened overall survival (p < 0.0001). Associations with outcome and tumor phenotype were inversely for papillary RCC, where TUBB3 immunostaining was linked to low tumor stage (p = 0.0012) and prolonged survival (p = 0.0043). CONCLUSIONS:TUBB3 expression levels and their effects are strikingly different between ccRCC and papillary RCC. These differences may be caused by differences in VHL function between these RCC subtypes, because VHL (like TUBB3) is another strong regulator of microtubule function.
Authors: Christian Ruiz; Silvia Seibt; Khawla Al Kuraya; Abdul K Siraj; Martina Mirlacher; Peter Schraml; Robert Maurer; Hanspeter Spichtin; Joachim Torhorst; Savelina Popovska; Ronald Simon; Guido Sauter Journal: Int J Cancer Date: 2006-05-01 Impact factor: 7.396
Authors: H Moch; P Schraml; L Bubendorf; M Mirlacher; J Kononen; T Gasser; M J Mihatsch; O P Kallioniemi; G Sauter Journal: Am J Pathol Date: 1999-04 Impact factor: 4.307
Authors: Martijn P Lolkema; Niven Mehra; Anita S Jorna; Moniek van Beest; Rachel H Giles; Emile E Voest Journal: Exp Cell Res Date: 2004-12-10 Impact factor: 3.905
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Essel Dulaimi; Inmaculada Ibanez de Caceres; Robert G Uzzo; Tahseen Al-Saleem; Richard E Greenberg; Thomas J Polascik; James S Babb; William E Grizzle; Paul Cairns Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Agnieszka M Borys; Michał Seweryn; Tomasz Gołąbek; Łukasz Bełch; Agnieszka Klimkowska; Justyna Totoń-Żurańska; Julita Machlowska; Piotr Chłosta; Krzysztof Okoń; Paweł P Wołkow Journal: PLoS One Date: 2019-05-31 Impact factor: 3.240
Authors: Franziska Büscheck; Christoph Fraune; Seyedehmina Garmestani; Ronald Simon; Martina Kluth; Claudia Hube-Magg; Kathrin Ketterer; Christian Eichelberg; Doris Höflmayer; Frank Jacobsen; Corinna Wittmer; Waldemar Wilczak; Guido Sauter; Margit Fisch; Till Eichenauer; Michael Rink Journal: Ann Transl Med Date: 2021-02
Authors: Heike Loeser; Simon Schallenberg; Thomas Zander; Alexander Quaas; Moritz von Winterfeld; Lars Tharun; Hakan Alakus; Arnulf Hölscher; Elfriede Bollschweiler; Reinhard Buettner Journal: Oncotarget Date: 2017-12-11
Authors: Aleksandr Klepinin; Lyudmila Ounpuu; Kati Mado; Laura Truu; Vladimir Chekulayev; Marju Puurand; Igor Shevchuk; Kersti Tepp; Anu Planken; Tuuli Kaambre Journal: J Bioenerg Biomembr Date: 2018-07-12 Impact factor: 2.945